Paper Details

  1. Home
  2. Paper Details

Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.

Author: ChapmanJ R, CraigJ C, TaylorR S, WebsterA, WoodroffeR C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Kidney transplantation is the best treatment for most people with end-stage kidney disease. Standard treatment involves a combination of medications, each targeting a different part of the immune system to prevent rejection. While newer regimens are used, it's unclear if they are more specific or simply stronger at suppressing the immune system.
Paper Details　
Original Abstract of the Article :
Kidney transplantation is the treatment of choice for most patients with end-stage renal disease (ESRD). Standard protocols in use typically involve three drug groups each directed to a site in the T-cell activation or proliferation cascade which are central to the rejection process: calcineurin inh...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD003961.pub2

データ提供：米国国立医学図書館（NLM）

Tacrolimus vs. Cyclosporin: A Battle of Immunosuppressants in Kidney Transplantation

Kidney transplantation is a life-saving treatment for people with end-stage renal disease. It's like bringing a precious resource to a parched desert – giving a new lease on life. The challenge is to prevent rejection, the body's natural defense mechanism against foreign tissue. This research compares two immunosuppressant drugs, tacrolimus and cyclosporin, which work by suppressing the immune system's response to the transplanted kidney. Imagine these medications as a protective barrier around the oasis – preventing the surrounding desert from encroaching and destroying its precious resources.

Immunosuppressants: A Balancing Act in Kidney Transplantation

This study examines the efficacy of tacrolimus and cyclosporin as primary immunosuppressants for kidney transplant recipients. It's like comparing two different types of protective barriers – one might be stronger, but it might also have more side effects. The research highlights the importance of choosing the most appropriate immunosuppressant for each individual patient. It's like considering the unique characteristics of a desert – its temperature, wind patterns, and water availability – before deciding which type of barrier would best protect the oasis.

Choosing the Right Immunosuppressant

This research emphasizes the importance of careful consideration when choosing the appropriate immunosuppressant for kidney transplant recipients. It's like selecting the right camel for a desert journey – one that is strong, resilient, and suited to the specific terrain. The study underscores the need for more research to determine the optimal immunosuppressive regimen for each patient, ultimately enhancing the success rate of kidney transplantation.

Dr.Camel's Conclusion

This study delves into the complexities of immunosuppression in kidney transplantation, comparing two common medications, tacrolimus and cyclosporin. It's like exploring a vast desert, seeking the best path to protect a precious oasis. While both medications have their strengths and limitations, understanding their differences is crucial for selecting the most effective treatment for each patient.

Date :
  1. Date Completed 2006-02-24
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

16235347

DOI: Digital Object Identifier

10.1002/14651858.CD003961.pub2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.